Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase.

[1]  R. Sheridan,et al.  SQ: a program for rapidly producing pharmacophorically relevent molecular superpositions. , 1999, Journal of medicinal chemistry.

[2]  D. Pompliano,et al.  Potent, non-thiol inhibitors of farnesyltransferase. , 1998, Bioorganic & medicinal chemistry letters.

[3]  Zhanghua Wu,et al.  Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. , 1998, Biochemistry.

[4]  S. Ng,et al.  Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase. , 1998, Journal of medicinal chemistry.

[5]  T. Williams.  Inhibitors of protein farnesylation 1998 , 1998 .

[6]  S L Lin,et al.  Identification of novel farnesyl protein transferase inhibitors using three-dimensional database searching methods. , 1997, Journal of medicinal chemistry.

[7]  D M Leonard,et al.  Ras farnesyltransferase: a new therapeutic target. , 1997, Journal of medicinal chemistry.

[8]  P. Casey,et al.  Crystal Structure of Protein Farnesyltransferase at 2.25 Angstrom Resolution , 1997, Science.

[9]  A. Doherty,et al.  Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. , 1997, Journal of medicinal chemistry.

[10]  S. Graham,et al.  Patent Update Oncologic, Endocrine & Metabolic: Oncologic, Endocrine & Metabolic: Inhibitors of protein farnesylation , 1996 .

[11]  B. Seizinger,et al.  Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. , 1996, Journal of medicinal chemistry.

[12]  S. Graham.  Review Oncologic, Endocrine & Metabolic: Inhibitors of protein farnesylation: A new approach to cancer chemotherapy , 1995 .

[13]  A. Kral,et al.  Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice , 1995, Nature Medicine.

[14]  S. Sebti,et al.  Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase. , 1994, The Journal of biological chemistry.

[15]  N. Kohl,et al.  Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic , 1994, Cell.

[16]  J. Rizo,et al.  Conformation of a heptapeptide substrate bound to protein farnesyltransferase. , 1993, Biochemistry.

[17]  S. Sebti,et al.  Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics. , 1993, The Journal of biological chemistry.

[18]  R L Smith,et al.  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. , 1993, Science.

[19]  S. Rodenhuis.  ras and human tumors. , 1992, Seminars in cancer biology.

[20]  S. Moores,et al.  Sequence dependence of protein isoprenylation. , 1991, The Journal of biological chemistry.

[21]  J. Gibbs.  Ras C-terminal processing enzymes—New drug targets? , 1991, Cell.

[22]  P. Casey,et al.  Inhibition of purified p21 ras farnesyl:protein transferase by Cys-AAX tetrapeptides , 1990, Cell.

[23]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[24]  S. Sebti,et al.  Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. , 1997, Pharmacology & therapeutics.

[25]  B. Seizinger,et al.  Peptide based P21RAS farnesyl transferase inhibitors: systematic modification of the tetrapeptide CA1A2X motif , 1994 .

[26]  F. Stewart.  Synthesis of m-Aminomethylbenzoic Acid Peptides , 1983 .